Papulopustular Rosacea
Pipeline by Development Stage
Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.
Key Trends
- HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
- Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
- Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market
Career Verdict
Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | HUMIRA (adalimumab) | AbbVie | $258M | 88% | LOE_APPROACHING | Declining | |
| 2 | VTAMA (tapinarof) | Merck & Co. | $19M | 6% | PEAK | Growing | 13.5yr |
| 3 | ORACEA (doxycycline) | Galderma | $4M | 1% | LOE_APPROACHING | Declining | 1.6yr |
Drug Class Breakdown
Patent cliff looming
Emerging innovation
Mature segment
Niche applications
Career Outlook
StableDermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.
Breaking In
Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.
For Experienced Professionals
Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.
In-Demand Skills
Best For
Hiring Landscape
Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.
By Department
Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.
On Market (2)
Approved therapies currently available
Competitive Landscape
9 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 22 trials with date data
Clinical Trials (22)
Total enrollment: 6,517 patients across 22 trials
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Phase 3 Papulopustular Rosacea Study
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
A Twelve Week Safety and Efficacy Study in Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
Study to Evaluate the Safety of ATR-04
A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Related Jobs in Dermatology
Specialty Sales Representative (Indianapolis, IN)
Territory Manager - Bakersfield
Process Expert (m/f/d) - Schaftenau, Tirol
Territory Manager - Chicago South
Specialty Sales Representative (Birmingham, AL - West)
District Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.